Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

What's the purpose of the trial?

This Phase 1, first-in-human (FIH), clinical study of CC-92328 will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM).

Trial status

Accepting patients

Phase 1
Last Updated
3 weeks ago
Am I Eligible

Participating Centers

There are 6 centers participating in this trial. Enter a location below to find the closet center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • CC-92328

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

CC-92328 Dose Escalation

Not yet accepting

CC-92328 Dose Expansion

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.